Immunotherapies strengthen a patient’s immune system to detect and attack tumors. AbbVie is researching various approaches to trigger immune cells to be activated only in the tumor itself.
Apoptosis, or programmed cell death, is an essential natural process to eliminate damaged, unneeded or infected cells from the body. For more than 20 years, AbbVie’s scientists have pioneered research on how to activate apoptosis in cancer cells.
Cancer Stem Cells
Cancer stem cells are cells responsible for tumor initiation. AbbVie is utilizing its large tumor bank of patient derived tumor models to identify novel cancer stem cells and develop selective medicines that target these cells.
Antibody Drug Conjugates (ADCs)
ADCs are monoclonal antibodies (mAbs) that bind directly to specific markers on a cancer cell and deliver a cytotoxic agent. ADCs could allow us to direct the therapy straight to the intended tumor target.
A bispecific is a biological therapy that combines the function of two different antibodies to target different tumor cell markers on diseased tissue. With our bispecifics platform, we can create a wide range of protein constructs leading to new biology with different mechanisms of action.
Antibodies are proteins that bind to specific markers (antigens) on tissue cells with the purpose of destroying the antigen. AbbVie’s antibody technologies enable us to develop highly targeted therapies.